Economic Impact


The high cost of Candida

A typical patient with a Candida infection averages 40 days in the hospital, including 9 days in intensive care, resulting in an average cost per hospital stay of over $130,000 per patient.1

In a study published in the American Journal of Respiratory and Critical Care Medicine, providing targeted antifungal therapy within 24 hours of the presentation of symptoms decreased the length of hospital stay by approximately 9 days2 and decreased the average cost of care by approximately $30,000 per patient.

In addition, many hospitals initiate antifungal drugs while waiting for blood culture-based diagnostic results. This practice is currently in use for over 40% of high-risk patients on average and for all high-risk patients in some hospitals. A negative result from the T2Candida Panel may provide timely data allowing physicians to avoid unnecessary antifungal treatment and potentially reduce the treatment costs by $500 or more per patient.4 

Rapid diagnosis saves money

A typical hospital may save $3+ Million per year with the T2Candida Panel*

T2Candida Rapid Positive Result

  • 8.8 day reduced length of stay2

    • 3.3 days reduced in ICU2

    • 5.5 days reduced in general ward2

  • $30,000 saved per patient3

T2Candida Negative Result

  • $500 saved per patient by discontinuing antifungals4

Rapid diagnosis saves lives

In a recent study published in Future Microbiology, early detection allowed for timely, accurate treatment as necessary, and cost avoidance when not needed. Rapid detection also demonstrated a reduction of 60.6 percent Candida-related deaths per hospital.4

1. Gagne, J. J., Breitbart, R. E., Maio, V., et. al. (2006). Costs associated with candidemia in a hospital setting. P and T, 31(10), 586.
2. Arnold, H. M., Micek, S. T., Shorr, A. F., et al. (2010). Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy: the journal of human pharmacology and drug therapy, 30(4), 361-368
3. Arnold, H. M., Micek, S. T., Shorr, A. F., et al. (2009). Hospital resource utilization and costs of inappropriate treatment of candidemia. American journal of respiratory and critical care medicine, 179, A2476.
4. Bilir, S. P., Ferrufino, C. P., Pfaller, M. A., & Munakata, J. (2015). The economic impact of rapid Candida species identification by T2Candida among high-risk patients.
* Savings may vary.